Insider Buying: Andean Precious Metals Corp. (CVE:APM) Insider Acquires 700,000 Shares of Stock

Andean Precious Metals Corp. (CVE:APM) insider 2176423 Ontario Ltd. acquired 700,000 shares of the company’s stock in a transaction dated Tuesday, September 24th. The shares were bought at an average price of C$1.36 per share, for a total transaction of C$952,000.00.

2176423 Ontario Ltd. also recently made the following trade(s):

• On Monday, September 16th, 2176423 Ontario Ltd. bought 204,600 shares of Andean Precious Metals stock. The shares were purchased at an average price of C$1.14 per share, for a total transaction of C$233,141.70.

Andean Precious Metals Stock Down 1.4 %

CVE APM traded down C$0.02 during trading on Wednesday, reaching C$1.41. 28,953 shares of the company’s stock were exchanged, compared to its average volume of 166,165. The firm’s 50 day simple moving average is C$1.06. The firm has a market capitalization of C$210.60 million, a PE ratio of 3.76 and a beta of 1.13. Andean Precious Metals Corp. has a fifty-two week low of C$0.53 and a fifty-two week high of C$1.49.

Andean Precious Metals (CVE:APM) last posted its earnings results on Tuesday, August 13th. The company reported C$0.08 earnings per share for the quarter, hitting analysts’ consensus estimates of C$0.08. Andean Precious Metals had a return on equity of 41.08% and a net margin of 23.75%. The business had revenue of C$95.47 million for the quarter. On average, analysts forecast that Andean Precious Metals Corp. will post 0.3801917 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Desjardins lifted their price objective on shares of Andean Precious Metals from C$1.60 to C$1.70 and gave the company a “buy” rating in a research report on Tuesday, September 3rd.

About Andean Precious Metals

Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diseases with a focus on infectious diseases and cancers. Its pipeline enables the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases.